(PSNL) Personalis - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 887m USD | Total Return: 90.6% in 12m

Genomic Tests, Liquid Biopsy, Cancer Sequencing, Tumor Profiling
Total Rating 24
Safety 29
Buy Signal -0.17
Diagnostics & Research
Industry Rotation: +1.9
Market Cap: 887M
Avg Turnover: 14.5M
Risk 3d forecast
Volatility108%
VaR 5th Pctl16.7%
VaR vs Median-6.28%
Reward TTM
Sharpe Ratio1.10
Rel. Str. IBD79.2
Rel. Str. Peer Group74.1
Character TTM
Beta3.915
Beta Downside2.195
Hurst Exponent0.520
Drawdowns 3y
Max DD63.39%
CAGR/Max DD1.12
CAGR/Mean DD2.36
EPS (Earnings per Share) EPS (Earnings per Share) of PSNL over the last years for every Quarter: "2021-03": -0.29, "2021-06": -0.34, "2021-09": -0.4, "2021-12": -0.45, "2022-03": -0.63, "2022-06": -0.6, "2022-09": -0.58, "2022-12": -0.67, "2023-03": -0.61, "2023-06": -0.5, "2023-09": -0.48, "2023-12": -0.54, "2024-03": -0.26, "2024-06": -0.24, "2024-09": -0.64, "2024-12": -0.23, "2025-03": -0.18, "2025-06": -0.23, "2025-09": -0.24, "2025-12": -0.26, "2026-03": -0.29,
Last SUE: -0.07
Qual. Beats: 0
Revenue Revenue of PSNL over the last years for every Quarter: 2021-03: 20.881, 2021-06: 21.67, 2021-09: 22.261, 2021-12: 20.682, 2022-03: 15.227, 2022-06: 18.24, 2022-09: 14.858, 2022-12: 16.722, 2023-03: 18.86, 2023-06: 16.699, 2023-09: 18.247, 2023-12: 19.675, 2024-03: 19.525, 2024-06: 22.58, 2024-09: 25.709, 2024-12: 16.8, 2025-03: 20.605, 2025-06: 17.203, 2025-09: 14.495, 2025-12: 17.345, 2026-03: 15.472,
Rev. CAGR: -0.57%
Rev. Trend: -5.0%
Last SUE: 0.44
Qual. Beats: 0

Warnings

Share dilution 19.1% YoY

Interest Coverage Ratio -435.5 is critical

Beneish M-Score -1.41 > -1.5 - likely earnings manipulation

Altman Z'' -14.23 < 1.0 - financial distress zone

Extended 1w Choppy

Tailwinds

No distinct edge detected

Description: PSNL Personalis

Personalis, Inc. (PSNL) is a life sciences company specializing in advanced genomic sequencing for cancer treatment and clinical research. Its core product suite includes the NeXT platform, which utilizes both liquid biopsy and tissue-based testing to monitor minimal residual disease (MRD), track therapy response, and identify biomarkers for personalized medicine. The company serves a diverse client base comprising pharmaceutical firms, diagnostic providers, and academic institutions.

The business operates within the precision oncology sector, a field characterized by high R&D intensity and a shift toward non-invasive liquid biopsies to replace traditional tissue sampling. Unlike standard genomic tests that target narrow gene panels, Personalis utilizes whole exome and transcriptome sequencing to provide a comprehensive view of the tumor microenvironment. This high-resolution data is critical for drug developers seeking to validate new immunotherapies and for clinicians managing long-term patient recurrence.

For a deeper look into the financial metrics and valuation of this company, you may wish to explore the data on ValueRay.

Headlines to Watch Out For
  • Adoption of NeXT Personal liquid biopsy test drives minimal residual disease market share
  • Strategic collaboration with Tempus AI expands commercial reach and clinical data utilization
  • Medicare reimbursement coverage decisions determine revenue scalability for genomic profiling services
  • Biopharmaceutical research and development spending levels impact core sequencing service volume
  • Cash burn rate and capital allocation influence long-term liquidity and valuation metrics
Piotroski VR-10 (Strict) 0.0
Net Income: -95.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.26 > 0.02 and ΔFCF/TA -8.92 > 1.0
NWC/Revenue: 339.7% < 20% (prev 206.0%; Δ 133.7% < -1%)
CFO/TA -0.24 > 3% & CFO -79.5m > Net Income -95.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.61 > 1.5 & < 3
Outstanding Shares: last quarter (104.2m) vs 12m ago 19.13% < -2%
Gross Margin: 13.72% > 18% (prev 0.33%; Δ 1.34k% > 0.5%)
Asset Turnover: 21.55% > 50% (prev 31.35%; Δ -9.80% > 0%)
Interest Coverage Ratio: -435.5 > 6 (EBITDA TTM -87.7m / Interest Expense TTM 224k)
Altman Z'' -14.23
A: 0.67 (Total Current Assets 258.2m - Total Current Liabilities 39.0m) / Total Assets 325.4m
B: -2.03 (Retained Earnings -661.3m / Total Assets 325.4m)
C: -0.33 (EBIT TTM -97.6m / Avg Total Assets 299.4m)
D: -9.36 (Book Value of Equity -661.4m / Total Liabilities 70.6m)
Altman-Z'' = -14.23 = D
Beneish M -1.41
DSRI: 1.58 (Receivables 13.0m/11.0m, Revenue 64.5m/85.7m)
GMI: 2.43 (GM 13.72% / 33.30%)
AQI: 1.12 (AQ_t 0.01 / AQ_t-1 0.01)
SGI: 0.75 (Revenue 64.5m / 85.7m)
TATA: -0.05 (NI -95.6m - CFO -79.5m) / TA 325.4m)
Beneish M = -1.41 (Cap -4..+1) = D
What is the price of PSNL shares?

As of May 27, 2026, the stock is trading at USD 8.94 with a total of 2,341,844 shares traded.
Over the past week, the price has changed by +33.04%, over one month by +50.00%, over three months by -1.00% and over the past year by +90.62%.

Is PSNL a buy, sell or hold?

Personalis has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy PSNL.

  • StrongBuy: 4
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the PSNL price?
Analysts Target Price 10.9 21.5%
Personalis (PSNL) - Fundamental Data Overview as of 26 May 2026
Market Cap USD = 887.0m (887.0m USD * 1.0 USD.USD)
P/S = 13.7486
P/B = 3.4816
Revenue TTM = 64.5m USD
EBIT TTM = -97.6m USD
EBITDA TTM = -87.7m USD
 Long Term Debt = unknown (none)
 Short Term Debt = 879k USD (from shortLongTermDebt, last quarter)
Debt = 68.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 37.9m
Net Debt = -164.3m USD (calculated: Debt 68.9m - CCE 233.2m)
Enterprise Value = 722.7m USD (887.0m + Debt 68.9m - CCE 233.2m)
Interest Coverage Ratio = -435.5 (Ebit TTM -97.6m / Interest Expense TTM 224k)
EV/FCF = -8.54x (Enterprise Value 722.7m / FCF TTM -84.6m)
FCF Yield = -11.71% (FCF TTM -84.6m / Enterprise Value 722.7m)
 FCF Margin = -131.2% (FCF TTM -84.6m / Revenue TTM 64.5m)
 Net Margin = -148.1% (Net Income TTM -95.6m / Revenue TTM 64.5m)
Gross Margin = 13.72% ((Revenue TTM 64.5m - Cost of Revenue TTM 55.7m) / Revenue TTM)
Gross Margin QoQ = 1.82% (prev 10.95%)
Tobins Q-Ratio = 2.22 (Enterprise Value 722.7m / Total Assets 325.4m)
Interest Expense / Debt = 0.32% (Interest Expense 224k / Debt 68.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -77.1m (EBIT -97.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.61 (Total Current Assets 258.2m / Total Current Liabilities 39.0m)
Debt / Equity = 0.27 (Debt 68.9m / totalStockholderEquity, last quarter 254.8m)
 Debt / EBITDA = 1.87 (negative EBITDA) (Net Debt -164.3m / EBITDA -87.7m)
 Debt / FCF = 1.94 (negative FCF - burning cash) (Net Debt -164.3m / FCF TTM -84.6m)
 Total Stockholder Equity = 219.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.92% (Net Income -95.6m / Total Assets 325.4m)
RoE = -10.85% (Net Income TTM -95.6m / Total Stockholder Equity 880.8m)
RoCE = -34.07% (EBIT -97.6m / Capital Employed (Total Assets 325.4m - Current Liab 39.0m))
 RoIC = -145.0% (out of range, set to none) (NOPAT -77.1m / Invested Capital 53.1m)
 WACC = 18.34% (E(887.0m)/V(955.9m) * Re(19.75%) + D(68.9m)/V(955.9m) * Rd(0.32%) * (1-Tc(0.21)))
Discount Rate = 19.75% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 39.30%
 [DCF] Fair Price = unknown (Cash Flow -84.6m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.07 | # QB: 0
Revenue Correlation: -5.03 | Revenue CAGR: -0.57% | SUE: 0.44 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.26 | Chg30d=+3.79% | Revisions=+11% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.24 | Chg30d=+10.48% | Revisions=+43% | Analysts=6
EPS current Year (2026-12-31): EPS=-1.02 | Chg30d=+4.70% | Revisions=+20% | GrowthEPS=-12.4% | GrowthRev=+13.1%
EPS next Year (2027-12-31): EPS=-0.90 | Chg30d=+5.22% | Revisions=-11% | GrowthEPS=+12.4% | GrowthRev=+41.0%
[Analyst] Revisions Ratio: +43%